Key Points
- BioSyent director Seyed Ahmad Ashrafi sold 700 shares at C$16.00 each on September 3, generating C$11,200. Following the transaction, he retained 30,361 shares valued at approximately C$485,776.
- Ashrafi has made several additional sales recently, including 100 shares on September 2 and a combined 3,284 shares across four transactions in June.
- BioSyent shares opened at C$15.97, near their 52-week high of C$16.25. The company had a market capitalization of about C$180.6 million and a price-to-earnings ratio of 18.70.
BioSyent Inc. (CVE:RX - Get Free Report) Director Seyed Ahmad Ashrafi sold 700 shares of the company's stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of C$16.00, for a total value of C$11,200.00. Following the completion of the sale, the director directly owned 30,361 shares of the company's stock, valued at approximately C$485,776. This represents a 2.25% decrease in their position.
Seyed Ahmad Ashrafi also recently made the following trade(s):
- On Wednesday, September 2nd, Seyed Ahmad Ashrafi sold 100 shares of BioSyent stock. The shares were sold at an average price of C$16.00, for a total transaction of C$1,600.00.
- On Tuesday, June 30th, Seyed Ahmad Ashrafi sold 1,884 shares of BioSyent stock. The stock was sold at an average price of C$14.65, for a total transaction of C$27,600.60.
- On Tuesday, June 30th, Seyed Ahmad Ashrafi sold 800 shares of BioSyent stock. The stock was sold at an average price of C$14.70, for a total transaction of C$11,760.00.
- On Tuesday, June 30th, Seyed Ahmad Ashrafi sold 600 shares of BioSyent stock. The stock was sold at an average price of C$14.50, for a total transaction of C$8,700.00.
BioSyent Price Performance
Shares of BioSyent stock opened at C$15.97 on Friday. BioSyent Inc. has a 52-week low of C$10.65 and a 52-week high of C$16.25. The stock has a market capitalization of C$180.60 million, a price-to-earnings ratio of 18.70 and a beta of 1.11. The company has a fifty day moving average of C$14.97 and a 200-day moving average of C$14.77. The company has a debt-to-equity ratio of 6.85, a quick ratio of 6.91 and a current ratio of 2.07.
About BioSyent
(
Get Free Report)
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
